Evidence map›Paper›PMID 30285835›Full record

ArticleTrials2018

Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced fetal movement at or after 36

Lindsay Armstrong-Buisseret, Eleanor Mitchell, Trish Hepburn, Lelia Duley, Jim G Thornton, Tracy E Roberts, Claire Storey, Rebecca Smyth, Alexander E P Heazell

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Lindsay Armstrong-BuisseretNottingham Clinical Trials Unit (NCTU), University of Nottingham, NHSP, C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH, UK.
Eleanor MitchellNottingham Clinical Trials Unit (NCTU), University of Nottingham, NHSP, C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH, UK.
Trish HepburnNottingham Clinical Trials Unit (NCTU), University of Nottingham, NHSP, C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH, UK.
Lelia DuleyNottingham Clinical Trials Unit (NCTU), University of Nottingham, NHSP, C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH, UK.
Jim G ThorntonNottingham Clinical Trials Unit (NCTU), University of Nottingham, NHSP, C Floor, South Block, Queens Medical Centre, Nottingham, NG7 2UH, UK.
Tracy E RobertsHealth Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Claire StoreyInternational Stillbirth Alliance, c/o Maternal and Fetal Health Research Centre, 5th Floor (Research), St Mary's Hospital, Oxford Road, Manchester, M13 9WL, UK.
Rebecca SmythSchool of Nursing, Midwifery and Social Work, Room 4. 329, Jean McFarlane Building, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.
Alexander E P HeazellMaternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester, M13 9WL, UK. alexander.heazell@manchester.ac.uk.ORCID http://orcid.org/0000-0002-4303-7845
University of Nottingham · GBUniversity of Manchester · GBSt Mary's Hospital · GBUniversity of Birmingham · GB

Funding

Department of Health CS-2013-13-009Research Trainees Coordinating Centre NIHR CS-2013-13-009
6 · The paper itself

Abstract

backgroundForty percent of babies who are stillborn born die after 36 weeks gestation and have no lethal structural abnormality. Maternal perception of reduced fetal movement (RFM) is associated with stillbirth and is related to abnormal placental structure and function. The ultimate objective of this trial is to assess whether for women with RFM, intervention directed by measurement of placental biochemical factors in addition to standard care improves pregnancy outcome compared with standard care alone. This is the protocol for a pilot trial to determine the feasibility of a definitive trial and also provide proof of concept that informing care by measurement of placental factors improves neonatal outcomes.

methodsReMIT-2 is a multicentre, pilot randomised controlled trial of care informed by results of an additional placental factor blood test versus standard care alone for women presenting with RFM at or after 36 DISCUSSION: Results from this pilot trial will help determine whether a large definitive trial is feasible. Such a study would provide evidence to guide management of women with RFM and reduce stillbirths.

trial registrationISRCTN Registry, ISRCTN12067514 . Registered on 8 September 2017.

Indexed as

Fetal MovementStillbirthBiomarkersFeasibility StudiesFemaleFetal DistressGestational AgeHospital MortalityHumansInfantInfant MortalityInfant, NewbornMulticenter Studies as TopicPilot ProjectsPlacenta Growth FactorPredictive Value of TestsBiomarkersPGF protein, humanPlacenta Growth FactorFeasibilityMaternal serumPerinatal mortalityPlacentaPlacental biomarkerReduced fetal movementsFlt-1/PlGF ratioStillbirth

Identifiers

PMID30285835
PMCPMC6167841
OpenAlexW2894046713

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.